Elucidation of Molecular Mechanism of the Nonopioid Β-Endorphin Action Using Synthetic Peptide TPLVTLFK
Publication year - 2019
Publication title -
journal of clinical and experimental immunology
Language(s) - English
Resource type - Journals
ISSN - 2475-6296
DOI - 10.33140/jcei.04.04.05
Subject(s) - receptor , agonist , chemistry , intracellular , peptide , mechanism of action , endocrinology , medicine , biochemistry , biology , in vitro
The review presents data on nonopioid action of β-endorphin and its synthetic fragment 12-19 (TPLVTLFK, octarphin), a selective agonist of a nonopioid β-endorphin receptor. Using tritium labeled octarphin, the receptor distribution in the body has been studied. It was discovered on immune cells (peritoneal macrophages, T and B-lymphocytes), endocrine (adrenal cortex, hypothalamus), cardiovascular (cardio myocytes) systems. Characteristics of the binding specificity showed that only unlabeled β-endorphin can displace the labeled octarphin from the complex with the receptor, the α-endorphin, γ-endorphin and enkephalins tested in parallel were inactive. The peptide was found to increase the activity of inducible NO-synthase (iNOS), soluble guanylate cyclase (sGC) and the content of cGMP in target cells. The results obtained suggest that the activating effect of octarphin and β-endorphin mediated through the nonopioid receptor is realized in the following way: increasing iNOS expression → increasing NO production → increasing sGC activity → increasing intracellular level of cGMP
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom